Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance

• Status: Unknown status
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to investigate the treatment response of metformin, Peg-IFN and ribavirin combination therapy for chronic hepatitis C virus (HCV).

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaohsiung Veterans General Hospital.
• Treatments: Interferon-alpha; Interferons; Metformin; Ribavirin

Criteria

Inclusion Criteria:

• HCV RNA (+) and ALT > 40 U/L

• Compensated liver

• HOMA-IR > 2

Exclusion Criteria:

• neutrophil <1500/mm3

• male: Hb < 13 g/dl, female: Hb < 12 g/dl

• platelet < 80,000 /mm3

• Cr > 2.5 mg/dl

• Alcohol use > 20 gm per day

• uncontrolled depression, thyroid disease, autoimmune disease

• Pregnancy

• Hepatocellular carcinoma

• allergy to interferon or ribavirin

• Diabetes

• HBV/HIV co-infection